Sponsored by the ÀÖ²¥´«Ã½ Office of Career Services, the talk is open to the public at no charge. A short networking session with refreshments follows. For more information, please call 207-786-6232.

A ÀÖ²¥´«Ã½ College trustee, Barlow is chairman and CEO of Molecular Insight, an emerging biopharmaceutical company focused on developing innovative molecular-imaging pharmaceuticals and targeted radiotherapeutics for cancer. Barlow joined the Cambridge, Mass.-based firm in March 2000 as chairman and added the CEO responsibilities in January 2003.

With more than a quarter-century of distinguished service in the global biopharmaceutical industry, Barlow has built high-performance companies and brought successful products from concept to global markets. He was previously president of Sepracor Pharmaceuticals, where he was instrumental in creating a strategy resulting in the first fully integrated chemistry-based pharmaceutical company in decades.

During his six-year tenure, Sepracor’s valuation increased from roughly $80 million to nearly $5 billion and its staff grew from 30 to several hundred employees. The firm created substantial corporate partnerships with such companies as Schering-Plough, Eli Lilly and J&J, and raised more than $500 million in the public market.

Barlow serves as a trustee of McLean Hospital and Newton Country Day School in addition to ÀÖ²¥´«Ã½, and is a member of the President’s Council at Massachusetts General Hospital. He earned his master’s in business from Stanford University Graduate School of Business, where he is a frequent lecturer on strategic public policy and the biopharmaceutical industry.

The ÀÖ²¥´«Ã½ College Seminar Series on Entrepreneurship presents David Barlow, a member of the college’s class of 1979 and the head of Molecular Insight Pharmaceuticals, Inc., in a discussion of his work at 7 p.m. Monday, April 26, in Chase Hall Lounge, Campus Avenue.

Sponsored by the ÀÖ²¥´«Ã½ Office of Career Services, the talk is open to the public at no charge. A short networking session with refreshments follows. For more information, please call 207-786-6232.

A ÀÖ²¥´«Ã½ College trustee, Barlow is chairman and CEO of Molecular Insight, an emerging biopharmaceutical company focused on developing innovative molecular-imaging pharmaceuticals and targeted radiotherapeutics for cancer. Barlow joined the Cambridge, Mass.-based firm in March 2000 as chairman and added the CEO responsibilities in January 2003.

With more than a quarter-century of distinguished service in the global biopharmaceutical industry, Barlow has built high-performance companies and brought successful products from concept to global markets. He was previously president of Sepracor Pharmaceuticals, where he was instrumental in creating a strategy resulting in the first fully integrated chemistry-based pharmaceutical company in decades.

During his six-year tenure, Sepracor’s valuation increased from roughly $80 million to nearly $5 billion and its staff grew from 30 to several hundred employees. The firm created substantial corporate partnerships with such companies as Schering-Plough, Eli Lilly and J&J, and raised more than $500 million in the public market.

Barlow serves as a trustee of McLean Hospital and Newton Country Day School in addition to ÀÖ²¥´«Ã½, and is a member of the President’s Council at Massachusetts General Hospital. He earned his M.B.A. from Stanford University Graduate School of Business, where he is a frequent lecturer on strategic public policy and the biopharmaceutical industry.

“ÀÖ²¥´«Ã½ students consider their study-abroad experience to be invaluable. When integrated with the hallmark academic rigor of the ÀÖ²¥´«Ã½ campus experience, study abroad instills the international perspective required to negotiate the diverse intellectual demands of today’s rapidly changing world,” Harward said, referring to the nearly six of every 10 ÀÖ²¥´«Ã½ students who study abroad during the course of their four years at ÀÖ²¥´«Ã½. Among America’s 3,400 colleges and universities, ÀÖ²¥´«Ã½ ranks among the top 10 in the percentage of students who pursue international study. “We are enormously grateful to the Barlows for drawing on their own experiences to enrich the opportunities possible for students far into the future. Students will find their lives changed because of the Barlows’ generosity.”

The Barlow Endowment will generate at least $75,000 yearly for the purpose of study abroad. Coincidentally, it dovetails with the planned senior gift of the class of 2000, which hopes to raise $25,000 in an endowed fund to provide additional support for students away in their junior year. When the Barlow gift was announced to ÀÖ²¥´«Ã½ senior class officers and their senior gift committee, “they responded with cheers,” said Vicky Devlin, vice president for development at ÀÖ²¥´«Ã½. “The Barlows’ gift is important on many levels,” Devlin said. “It strengthens the junior year abroad program; it signals the college’s commitment to global education; and it demonstrates leadership from a young alumnus.”

“Ann and I believe that younger alums should give back to their schools now rather than waiting for several years. This giving, be it time or any sum of money, allows you to directly participate in the institution’s mission. For those who have benefited by early business success, there are unlimited opportunities to meaningfully impact programs important to you,” Barlow said.

While at ÀÖ²¥´«Ã½, Barlow spent a transformational junior year at The University of Wales and traveled throughout Europe and North Africa. “The trains were my classroom,” he said. The experience “liberated my curiosity and ignited a hearty appetite for diversity and global citizenship.” He and his wife, Ann, who also spent her junior year of college abroad, hope that their gift will encourage “the connection of the study abroad experience to academic life and throughout adulthood. It affects how you view the world and experience other cultures,” Barlow said.

Their gift establishes the David S. and Ann M. Barlow Endowment for Study Abroad. Beginning with a pilot phase, the fund will support three initiatives at ÀÖ²¥´«Ã½. The Barlows Fellows Program will enable up to 10 Barlow Fellows to work with faculty advisers to develop a study abroad plan, including courses that might be taken prior to departure; pursue additional travel while abroad; and undertake activities that augment the experience upon their return to ÀÖ²¥´«Ã½. Faculty advisers also will have access to funds.

In addition, the Barlow Endowment will support specific areas of the study abroad sequence, including senior thesis research, internships and employment, and faculty travel to sites and programs frequently used by ÀÖ²¥´«Ã½ students. The Barlow funds will also provide support for students’ return to ÀÖ²¥´«Ã½, such as study abroad fairs, winter semester photography exhibits and speakers bureaus, providing returning students the opportunity to share their experiences with the college community as well as children and teachers in area public schools. “Study-abroad students have the potential to enrich the campus when they return,” said Stephen Sawyer, associate dean of students. “The Barlow Endowment will help ÀÖ²¥´«Ã½ realize this potential by integrating these experiences with the academic and social life on campus.”

Finally, the Barlow Endowment hopes to invest in the learning experiences of alumni through alumni study abroad symposia and grants for study abroad consistent with educational and professional goals.

David Barlow has had a distinguished career in the pharmaceutical industry. Beginning in Eastern Europe, he then worked for Pfizer Inc. before spearheading the turnaround of Rhône-Poulenc Rorer’s global Armour pharmaceutical division. Barlow then joined Sepracor in 1993 where, as general manger, then president, of pharmaceuticals, he played a key role in Sepracor’s growth into a fully integrated pharmaceutical company. Having left Sepracor in late 1999, Barlow is the president of Black Diamond Capital, a private investment firm. He is also chairman of the board of Pan Pacific Pharmaceuticals Inc. and Biostream Inc., both rapidly emerging private healthcare companies, along with being a board member of two public companies, Enzon Inc. and Hemasure Inc.

Ann Barlow, a graduate of the College of Mount St. Vincent, has an M.B.A. from Rutgers University and is involved in several projects concerning education for children.

The Barlows have also recently endowed the David S. and Ann M. Barlow Professorship in Management at the Stanford University Graduate School of Business, from which Barlow is a 1985 M.B.A. graduate.